Commentary
Video
Translational Science Reshaping the 2025 PNS Annual Meeting Agenda: Kathrin Doppler, MD; Vincent Timmerman, PhD, MSc
Author(s):
Key Takeaways
- The PNS Annual Meeting is the largest global event focused on peripheral nerve biology and medicine, scheduled for May 17-20 in Edinburgh, Scotland.
- Recent advancements include gene therapies for Charcot-Marie-Tooth disease, immunomodulatory treatments, and targeted therapies like small molecules and CAR T-cell therapies.
A pair of committee chairs for the Peripheral Nerve Society’s Annual Meeting discussed how this year’s meeting reflects a growing emphasis on therapeutic research and translational progress in peripheral neuropathies. [WATCH TIME: 2 minutes]
WATCH TIME: 2 minutes
"We’re seeing a convergence of science and clinical care—treatments are now catching up to decades of diagnostic discovery in peripheral neuropathies."
The Peripheral Nerve Society (PNS) Annual Meeting is the world’s largest scientific gathering focused on peripheral nerve biology and medicine. Established in 1994, the PNS comprises scientists, clinicians, and healthcare providers dedicated to advancing the understanding and treatment of peripheral nervous system disorders. This year’s meeting, expected to be the largest PNS meeting to date, is scheduled for May 17-20 at the Edinburgh International Conference Centre in Edinburgh, Scotland.
The event will offer a platform for clinicians and scientists to exchange ideas, access unpublished data, and align clinical and scientific priorities for peripheral nerve disorders. In recent years, the field has seen progress in the development of gene therapies, particular in conditions like Charcot-Marie-Tooth disease, as well as immunomodulatory treatments, and targeted therapies like small molecules and CAR T-cell therapies.
Ahead of the meeting, NeurologyLive® sat down with committee chairs Kathrin Doppler, MD, and Vincent Timmerman, PhD, MSc, who spoke on the evolving focus of this year’s meeting, and how it may differ from previous iterations. Doppler, a neurologist at the University Hospital of Wurzburg, in Germany, and Timmerman, a professor at the University of Antwerp, in Belgium, noted a clear shift from predominantly diagnostic and biomarker research to a broader emphasis on treatment strategies. Both experts emphasized the growing convergence of basic science and clinical application, pointing to a more translational agenda that aims to expand treatment possibilities.
Observed Differences in PIRA Definition Call for More Standardized Agreement on Term
